Renal confidence drives DOAC selection more than guidelines suggest.
When renal function is borderline (CrCl 30–50), physicians cluster around apixaban for "comfort" reasons that exceed the published evidence. They describe checking the CrCl as a "gut check" rather than a dose-adjustment trigger.
"Apixaban just feels safer in renal. I know the data is mixed but it's where I land."Dr. K. Watanabe · Cardiology, WA · 11 yrs
"If their CrCl is under 50 I'm not even thinking about rivaroxaban. It's apixaban or warfarin."Dr. L. Okonkwo · Cardiology, NJ · 9 yrs